Back Login to subscribe 🔔 Set Alert

JAZZ Jazz Pharmaceuticals plc Common Stock (Ireland)

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	Jazz Pharmaceuticals Announces New Data Published In The New England Journal Of Medicine Showing Positive Results Of Ziihera In Combination With Chemotherapy For Treatment Of Gastroesophageal Adenocarcinoma	93.02%
	Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $253	77.59%
	Bernstein Initiates Coverage On Jazz Pharmaceuticals with Market Perform Rating, Announces Price Target of $229	59.72%
	Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $301	62.86%
	Jazz Pharmaceuticals shares are trading higher after UBS upgraded the stock from Neutral to Buy rating and raised its price target from $188 to $307.	95.17%
	ALX Oncology Holdings Announces New Data Supporting Phase 1b/2 Clinical Trial For Evoracept In Combination With Jazz Pharmaceutical's Zanidatamab For Patients With Pre-Treated HER2-Positive Metastatic Breast Cancer	91.19%
	TD Cowen Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $275	76.91%
	Jazz Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript	93.93%
	Jazz Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 financial results.	95.81%
	Jazz Pharmaceuticals Affirms FY2026 Sales Guidance of $4.250B-$4.500B vs $4.445B Est	62.33%

1
2
›